

Uppsala 2024-05-29

## **DBP International AB: European patent for the technology platform BeloGal® is granted**

Double Bond Pharmaceutical International AB (publ) ("DBP" or the "Company", org. no. 556991-6082) has today, May 29, 2024, received information about the granting of a European patent application for organ-specific administration of hydrophilic cancer drugs to the liver. This applies, among other things, to one of the company's frontline products SA-033 for the treatment of liver cancer, which is based on the technology platform BeloGal®. The patent approval means protection for the product in 26 countries within the European Patent Office (EPO) at least until the year 2035.

*"The granted patent concerns the geographically most important market in the world and we have reached an important milestone for the commercialization of our frontline product SA-033 for the treatment of liver cancer," comments Igor Lokot, CEO of Double Bond Pharmaceutical.*

**More about SA-033:** SA-033 is the first drug candidate that DBP has developed using its innovative drug delivery technology BeloGal®. Due to innovative formulation controls targeting of doxorubicin to the liver, the concentration of the active substance in the desired target organ increases, which enhances efficacy and reduces the toxic side effects that are common in systemic chemotherapy.

**More about BeloGal®:** BeloGal® is DBP's innovative drug-delivery platform which targets pharmaceutically active compounds to lung or liver.

*This information is information that Double Bond Pharmaceutical International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 29 of May 2024.*

---

**Full Company Name:** Double Bond Pharmaceutical International AB (publ)

**Corporate identity:** 556991-6082

**Stock short name:** DBP B

**Share ISIN code:** SE0007185525



For more info, contact

Igor Lokot, CEO

Homepage: <http://www.doublebp.com/>

**E-mail: [info@doublebp.com](mailto:info@doublebp.com)**

---

### **Information on Double Bond Pharmaceutical International AB**

DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company's own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.